NCT03742245: Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

NCT03742245
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with HER2+ breast cancer; Patients with uncontrolled brain or leptomeningeal metastases; Patients with any previous treatment of a PARP inhibitor (e.g. olaparib) or HDAC inhibitor (e.g. vorinostat)
https://ClinicalTrials.gov/show/NCT03742245

Comments are closed.

Up ↑